Department of Electromyography, Foshan Hospital of Traditional Chinese Medicine, Guangdong Province, China.
Department of Neurology, Guangdong Provincial People's Hospital Nanhai Hospital, The Second People's Hospital of Nanhai District Foshan City, Guangdong Province, China.
Clin Ther. 2022 Apr;44(4):482-490. doi: 10.1016/j.clinthera.2022.02.012. Epub 2022 Mar 25.
Cinnamon can reduce levels of blood lipids, blood glucose, and inflammation, which are risk factors for ischemic stroke and transient ischemic attack (TIA).The goal of this study was to observe the safety and efficacy of aspirin combined with cinnamon in the treatment of patients with mild stroke or TIA.
This pilot study included patients with mild stroke or TIA treated at Guangdong Provincial People's Hospital-Nanhai Hospital between January 2014 and December 2016. The primary end point was recurrent stroke (within 90 days after the first attack; intention-to-treat analysis). The secondary end points included biochemical indices, carotid color Doppler ultrasound, safety indices, and adverse reactions.
A total of 122 patients were included, including 62 in the aspirin-cinnamon group (41 men and 21 women; mean age, 62.0 [3.5] years) and 60 in the aspirin-placebo group (40 men and 20 women; mean age, 63.0 [3.2] years). The number of participants with recurrent stroke was two (3.2%) and nine (15.0%) in the aspirin-cinnamon group and the aspirin-placebo group, respectively (P = 0.002). Compared with aspirin-cinnamon, aspirin-placebo rates of unstable plaque and severe vascular stenosis were higher, whereas the rate of mild vascular stenosis with aspirin-cinnamon was higher than with aspirin-placebo (P < 0.05). One case of mild to moderate upper gastrointestinal bleeding in each group was observed.
Among patients with TIA or mild ischemic stroke, the combination of cinnamon and aspirin could be superior to aspirin alone for reducing the risk of 90-day recurrent stroke.
肉桂可以降低血脂、血糖和炎症水平,这些都是缺血性卒中和短暂性脑缺血发作(TIA)的风险因素。本研究的目的是观察阿司匹林联合肉桂治疗轻度卒中和 TIA 患者的安全性和疗效。
本初步研究纳入了 2014 年 1 月至 2016 年 12 月在广东省人民医院南海医院治疗的轻度卒中和 TIA 患者。主要终点为复发性卒中(首次发作后 90 天内;意向治疗分析)。次要终点包括生化指标、颈动脉彩色多普勒超声、安全性指标和不良反应。
共纳入 122 例患者,其中阿司匹林-肉桂组 62 例(41 例男性,21 例女性;平均年龄 62.0[3.5]岁),阿司匹林安慰剂组 60 例(40 例男性,20 例女性;平均年龄 63.0[3.2]岁)。阿司匹林-肉桂组和阿司匹林安慰剂组的复发性卒中患者分别为 2 例(3.2%)和 9 例(15.0%)(P=0.002)。与阿司匹林-肉桂相比,阿司匹林-安慰剂不稳定斑块和严重血管狭窄的发生率较高,而阿司匹林-肉桂轻度血管狭窄的发生率高于阿司匹林-安慰剂(P<0.05)。两组各有 1 例轻度至中度上消化道出血。
在 TIA 或轻度缺血性卒中老年患者中,肉桂与阿司匹林联合应用可能优于阿司匹林单药治疗,降低 90 天内复发性卒中的风险。